Source data for the Viral hepatitis elimination barometer among people who inject drugs in Europe
This data bundle contains all source data used on the page, Viral hepatitis elimination barometer among people who inject drugs in Europe.
All data tables are made available in CSV format. Tables are presented first with their individual methodological notes. A bulk download version is also available further down this page.
All tables in CSV format with methodological notes.
Method of estimation
TM: treatment multiplier; CR: capture-recapture; TP: truncated Poisson; CM: combined methods; HM: HIV multiplier; MM: mortality multiplier; MIM: multivariate indicator method; OT: other
The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.
Average of available studies (63.30 per 1000 people)
The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.
Average of available studies (60.64 per 1000 people)
The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.
Average of available studies (37.87 %)
The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.
Average of available studies (5.20 %)
The level of evidence is assessed separately for seroprevalence studies (SP) and routine diagnostic tests (DT), based on the case definition for people who inject drugs, sample size, type of settings, number of sites, type of biological sample. SP are also assessed for sampling method; and DT for timeliness, periodicity and geographical coverage.
Average of available studies (2.76 %)
The coverage is based on the latest national estimates of injecting drug use and high-risk opioid use matched by harm reduction activity data (within a maximum of 2 years). The estimate of coverage of opioid agonist treatment for Belgium is derived from a subnational study conducted in 2019.
WHO 2020 target for needles and syringe distribution per person who injects drugs = 200
WHO 2020 the proportion of high-risk opioid users receiving opioid agonist treatment = 0.4
WHO 2020 target for the proportion of high-risk opioid users receiving opioid agonist treatment = 0.4
WHO 2020 target for needles and syringe distribution per person who injects drugs = 200
- Table HEB-24-1. Estimated number of people who inject drugs and prevalence of injecting drug use by country, 2022 or latest available data
- Table HEB-24-2. Sero-prelance studies. Prevalence of HCV antibodies among people who inject drugs, by country, 2021 or latest available data
- Table HEB-24-3. Routine diagnostic tests. Prevalence of HCV antibodies among people who inject drugs, by country, 2022 or latest available data
- Table HEB-24-4. Prevalence (%) of active HCV infection (HCV RNA+) among people who inject drugs, by country, 2022 or latest available data
- Table HEB-24-5. Sero-prevalence studies: Prevalence (%) of active HBV infection (HBsAg+) among PWID, by country, 2022 or latest available data
- Table HEB-24-6. Routine diagnostic testing studies: Prevalence (%) of active HBV infection (HBsAg+) among PWID, by country, 2021 or latest available data
- Table HEB-24-7. Countries with viral hepatitis policy inclusive of people who inject drugs, 2022
- Table HEB-24-8. Needle and syringe distribution and opioid agonist treatment coverage in relation to WHO 2020 targets, 2022 or latest available estimate
- Table HEB-24-9. Proportion of high-risk opioid users in opioid agonist treatment (OAT), European countries, 2022 or latest available data
- Table HEB-24-10. Number of syringes distributed per year per PWID, European countries, 2022 or latest available data
- Table HEB-24-11. Existence of a vaccination programme that provides access to HBV vaccination to people in prisons in 2022
- Table HEB-24-12. Percentage of people entering drug treatment reporting injecting drugs who had an HCV test in the previous 12 months, 2022 or latest data available
- Table HEB-24-13. Countries with restrictive clinical or reimbursement guidelines for Direct-acting antiviral agents (DAA) access for people who use drugs, 2024
- Table HEB-24-14. Trends in HCV antibody prevalence (%) among people who inject drugs aged less than 25 years: results from diagnostic tests and seroprevalence studies with national or multi-city coverage, 2014-2022
- Table HEB-24-15. Trends in HCV antibody prevalence (%) among people who inject drugs, injecting for less than 2 years: results from diagnostic tests and seroprevalence studies with national or multi-city coverage, 2014-2022
- Table HEB-24-16. Trends in HCV RNA prevalence (%) among people who inject drugs: results from diagnostic tests and seroprevalence studies with national or multi-city coverage, 2014-2022
- Table HEB-24-17. Overview of hepatitis elimination situation by country